Your browser doesn't support javascript.
The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
Basaran, Seniha; Simsek-Yavuz, Serap; Mese, Sevim; Çagatay, Atahan; Medetalibeyoglu, Alpay; Öncül, Oral; Özsüt, Halit; Agaçfidan, Ali; Gül, Ahmet; Eraksoy, Haluk.
  • Basaran S; Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: senihabasaran@yahoo.com.
  • Simsek-Yavuz S; Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Mese S; Department of Medical Microbiology, Division of Virology and Fundamental Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Çagatay A; Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Medetalibeyoglu A; Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Öncül O; Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Özsüt H; Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Agaçfidan A; Department of Medical Microbiology, Division of Virology and Fundamental Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Gül A; Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Eraksoy H; Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Int J Infect Dis ; 105: 756-762, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1135367
ABSTRACT

OBJECTIVES:

Disease severity, previous medications and immunosuppressive agents could affect the antibody response against SARS-CoV-2. This study aimed to analyze variables affecting the humoral response to SARS-CoV-2.

METHODS:

This prospective cohort study included adult patients who recovered from COVID-19 and were admitted to a COVID-19 follow-up unit. Eight patient groups were defined in accordance with the results of thoracic computed tomography (CT), SARS-CoV-2 PCR test, and tocilizumab or anakinra use during active disease. Anti-S IgG antibodies were determined by ELISA in serum samples. Anti-S positive and negative cases were compared.

RESULTS:

A total of 518 patients were included in the study. SARS-CoV-2 IgG antibodies were positive in 82.8% of patients. SARS-CoV-2 PCR positivity, extent of lung involvement on CT, and time to antibody testing were independently associated with antibody positivity. Tocilizumab, anakinra or prednisolone use was not a factor affecting the antibody response. The rate of antibody response and sample/CO values among antibody-positive patients showed a linear relationship with the extent of lung involvement on CT.

CONCLUSIONS:

The use of tocilizumab, anakinra and prednisolone for COVID-19 did not affect the antibody response against SARS-CoV-2. The main driver of antibody response among patients with COVID-19 was the extent of pulmonary involvement on CT.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prednisolone / Interleukin 1 Receptor Antagonist Protein / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Female / Humans / Male / Middle aged Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Prednisolone / Interleukin 1 Receptor Antagonist Protein / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Drug Treatment / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Female / Humans / Male / Middle aged Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article